FMS News and Press, Fresenius Medical Care AG From 03/06/23

Fresenius Kidney Care Renews Commitment to Kidney Health Education with Second Year Boys & Girls Clubs of America National Partnership Fresenius Kidney Care Renews Commitment to Kidney Health Education with Second Year Boys & Girls Clubs of America National Partnership PR Ne...

OTTAWA, ON / ACCESSWIRE / February 24, 2023 / Focus Graphite Inc. (TSXV:FMS) ("Focus Graphite" or the "Company") announces that on February 23, 2023 the Board of Directorsadopted an amended stock option plan (the "Amended Option Plan") which will replace the Company's current option plan. The A...

Fresenius Medical Care AG & Co. KGaA (FMS) Q4 2022 Earnings Conference Call February 22, 2023 09:30 AM ET Company Participants Dominik Heger - Head, Investor Relations Helen Giza - Chair & Chief Executive Officer Conference Call Participants Graham Doyl...

The following slide deck was published by Fresenius Medical Care AG & Co. KGaA in conjunction with their 2022 Q4 earnings call. For further details see: Fresenius Medical Care AG & Co. KGaA 2022 Q4 - Results - Earnings Call Presentation

Fresenius Medical Care ( NYSE: FMS ) stock rose ~5% premarket on Wednesday after the company announced plans of restructuring and cost saving targets amid its Q4 results. Fresenius said it has implemented its new operating model with two global segments: Care Enablement (Health Ca...

Fresenius Medical Care ( NYSE: FMS ) is scheduled to announce Q4 earnings results on Wednesday, February 22nd, before market open. The consensus EPS Estimate is $0.23 (-74.4% Y/Y) and the consensus Revenue Estimate is $5.39B (+16.2% Y/Y). Over the last 2 years, FMS has beate...

Summary It’s among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie. Several drugmakers are expected to begin offering biosimilar ver...

Summary Tweedy, Browne’s 13F portfolio value decreased from $2.27B to $1.88B this quarter. They increased Ionis Pharmaceuticals while reducing most of the other stakes. Berkshire Hathaway at ~20% of the portfolio is the largest position. This article is part of a se...

Summary During the fourth quarter, we purchased shares in DaVita. DaVita and Fresenius control a combined 80% of the $25 billion U.S. dialysis market. DaVita runs its business at relatively healthy low-teens operating margins. Assuming no revenue growth, we estimate DVA’s...

Les excellents résultats des cinq (5) premiers sondages profonds suivant l'axe longitudinal du gisement de graphite du Corridor graphitique de Manicouagan-Ouest (CGMO) démontrent une fois de plus le potentiel pour une extension significative du gisement en profondeur. KINGSTON, ON /...